{"id":114086,"date":"2025-10-10T20:08:07","date_gmt":"2025-10-10T20:08:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/114086\/"},"modified":"2025-10-10T20:08:07","modified_gmt":"2025-10-10T20:08:07","slug":"fda-upgrades-recall-for-tens-of-thousands-of-bottles-of-commonly-prescribed-medication","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/114086\/","title":{"rendered":"FDA upgrades recall for tens of thousands of bottles of commonly prescribed medication"},"content":{"rendered":"<p>CINCINNATI (WKRC) &#8211; The FDA upgraded a recall for a commonly prescribed medication that may pose a health risk.<\/p>\n<p>According to an <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/ires\/index.cfm?Product=216116\" target=\"_blank\" title=\"https:\/\/www.accessdata.fda.gov\/scripts\/ires\/index.cfm?Product=216116\" class=\"themeColorForLinks\" rel=\"nofollow noopener\">updated enforcement report<\/a> from the Food and Drug Administration, 54,532 bottles of levothyroxine sodium tablets were recalled because they were sub-potent, or not as strong as advertised. The recall was initially issued on September 16, but was upgraded to a Class II recall on October 8.<\/p>\n<p>Class II recalls refer to &#8220;a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,&#8221; according to the<a href=\"https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\" target=\"_blank\" title=\"https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\" class=\"themeColorForLinks\" rel=\"nofollow noopener\"> FDA website<\/a>.<\/p>\n<p>The specific product recalled was &#8220;Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.&#8221;<\/p>\n<p>The FDA issued a similar recall on July 14 for over 160,000 bottles of levothyroxine sodium tablets also manufactured by Intas Pharmaceuticals.<\/p>\n<p>Levothyroxine sodium tablets are used to treat hypothyroidism, a disorder in which the thyroid does not produce enough hormones, according to <a href=\"https:\/\/www.theepochtimes.com\/us\/fda-upgrades-recall-on-54000-bottles-of-common-thyroid-medication-5927159?utm_source=atcn&amp;utm_content=hw1016multicomp&amp;utm_medium=email&amp;utm_campaign=atc&amp;utm_term=hws1comp\" target=\"_blank\" title=\"https:\/\/www.theepochtimes.com\/us\/fda-upgrades-recall-on-54000-bottles-of-common-thyroid-medication-5927159?utm_source=atcn&amp;utm_content=hw1016multicomp&amp;utm_medium=email&amp;utm_campaign=atc&amp;utm_term=hws1comp\" class=\"themeColorForLinks\" rel=\"nofollow noopener\">the Epoch Times<\/a>. The drug works as a form of hormone therapy, the outlet reported.<\/p>\n","protected":false},"excerpt":{"rendered":"CINCINNATI (WKRC) &#8211; The FDA upgraded a recall for a commonly prescribed medication that may pose a health&hellip;\n","protected":false},"author":2,"featured_media":114087,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[70377,18,2898,135,19,17,462,23278,514,2842],"class_list":{"0":"post-114086","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-class-ii","9":"tag-eire","10":"tag-fda","11":"tag-health","12":"tag-ie","13":"tag-ireland","14":"tag-medication","15":"tag-recall","16":"tag-sodium","17":"tag-tablets"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/114086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=114086"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/114086\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/114087"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=114086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=114086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=114086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}